Life sciences company EKF Diagnostics Holdings plc (AIM: EKF) has acquired technology assets from Sweden-based Beep Insights AB, including its iOS and Android application designed for real-time glucose and lactate tracking in sports performance monitoring.
The Beep Insights Technology integrates data from Bluetooth-connected wearables with biomarker tracking to deliver personalised training metrics. The acquisition is expected to enhance EKF's existing Sports Performance portfolio, particularly its Lactate Scout Sport handheld analyser, which is already compatible with the application.
EKF has collaborated with Beep Insights and its chief executive officer, Peter Alex, to integrate the software and improve accessibility in determining lactate threshold and optimising training outcomes. Following completion of the transaction, Alex will join EKF to support further development, including the application of artificial intelligence in performance training.
Headquartered in Penarth, Wales, EKF Diagnostics is a global diagnostics business specialising in point-of-care analysers for haematology and diabetes. The company operates manufacturing sites in the US and Germany and serves customers in more than 120 countries.
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
AROA Biosurgery completes Symphony trial in patients with diabetic foot ulcers
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Kodiak Sciences reports positive Phase 3 results for Zenkuda in diabetic retinopathy
Maze Therapeutics reports positive Phase 2 data for MZE829 in patients with AMKD
Andel launches new direct-to-employer medication platform for GLP-1s
Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026
Cedar Health Research opens new embedded research site within Texas Native Health
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Alvotech reaches global settlement over aflibercept biosimilar patents
MedPal AI announces approval to supply Eli Lilly medicines in UK
Hanmi Pharmaceutical signs distribution agreement with Laboratorios Sanfer in Mexico
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735